A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases

European Journal of Cancer

Volumn 50, Issue 2, 2014, Pages 277-289

  Aurilio, Gaetano ^a   Disalvatore, Davide ^a   Pruneri, Giancarlo ^a,b   Bagnardi, Vincenzo ^a,c   Viale, Giuseppe ^a,b   Curigliano, Giuseppe ^a   Adamoli, Laura ^a   Munzone, Elisabetta ^a   Sciandivasci, Angela ^a   De Vita, Fernando ^d   Goldhirsch, Aron ^a   Nolè, Franco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Breast cancer; Concordance; HER2; Hormone receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; DISTANT METASTASIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 84891781085     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.004     Document Type: Article

References (66)

1. P.P. Rosen, C.J. Menendez-Botet, J.A. Urban, A. Fracchia, and M.K. Schwartz Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer Cancer 39 5 1977 2194 2200
2. D.J. Webster, D.G. Bronn, and J.P. Minton Estrogen receptor levels in multiple biopsies from patients with breast cancer Am J Surg 136 3 1978 337 338
3. M.F. Freeman, and J.W. Tukey Transformations related to the angular and the square root Ann Math Stat 21 1950 607 611
4. J.J. Miller The inverse of the Freeman-Tukey double arcsine transformation Am Stat 32 1978 138
5. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 3 1986 177 188
6. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta analyses BMJ 327 7414 2003 557 560
7. S. Greenland Quantitative methods in the review of epidemiologic literature Epidemiol Rev 9 1987 1 30
8. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 7109 1997 629 634
9. I.M. Holdaway, and J.V. Bowditch Variation in receptor status between primary and metastatic breast cancer Cancer 52 3 1983 479 485
10. B.G. Mobbs, E.B. Fish, K.I. Pritchard, G. Oldfield, and W.H. Hanna Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment Eur J Cancer Clin Oncol 23 6 1987 819 826
11. J. Andersen, and H.S. Poulsen Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer Acta Oncol 27 6A 1988 761 765
12. C. Kamby, B.B. Rasmussen, and B. Kristensen Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence Br J Cancer 60 2 1989 252 257
13. G.A. Niehans, T.P. Singleton, D. Dykoski, and D.T. Kiang Stability of HER-2/neu expression over time and at multiple metastatic sites J Natl Cancer Inst 85 15 1993 1230 1235
14. B.D. Li, A. Byskosh, A. Molteni, and R.B. Duda Estrogen and progesterone receptor concordance between primary and recurrent breast cancer J Surg Oncol 57 2 1994 71 77
15. S.R. Johnston, G. Saccani-Jotti, and I.E. Smith et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer Cancer Res 55 15 1995 3331 3338
16. L. Nedergaard, T. Haerslev, and G.K. Jacobsen Immunohistochemical study of estrogen receptors in primary breast carcinomas and their lymph node metastases including comparison of two monoclonal antibodies APMIS 103 1 1995 20 24
17. T. van Agthoven, M. Timmermans, L.C. Dorssers, and S.C. Henzen-Logmans Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer Int J Cancer 63 6 1995 790 793
18. T. Kuukasjärvi, J. Kononen, H. Helin, K. Holli, and J. Isola Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 14 9 1996 2584 2589
19. S. Masood, and M.M. Bui Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study Ann Clin Lab Sci 30 3 2000 259 265
20. C. Shimizu, T. Fukutomi, and H. Tsuda et al. C-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues J Surg Oncol 73 1 2000 17 20
21. R. Simon, A. Nocito, and T. Hübscher et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 15 2001 1141 1146
22. M. Tanner, P. Järvinen, and J. Isola Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer Cancer Res 61 14 2001 5345 5348
23. W.Q. Zheng, J. Lu, J.M. Zheng, F.X. Hu, and C.R. Ni Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression Steroids 66 12 2001 905 910
24. D. Gancberg, A. Di Leo, and F. Cardoso et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 7 2002 1036 1043
25. A. Vincent-Salomon, M. Jouve, and P. Genin et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process Cancer 94 8 2002 2169 2173
26. S.M. Edgerton, D. Moore 2nd, D. Merkel, and A.D. Thor ErbB-2 (HER-2) and breast cancer progression Appl Immunohistochem Mol Morphol 11 3 2003 214 221
27. C. Iguchi, Y. Nio, and M. Itakura Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome J Surg Oncol 83 2 2003 85 93
28. Y. Sekido, S. Umemura, and S. Takekoshi et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation Int J Oncol 22 6 2003 1225 1232
29. J. Carlsson, H. Nordgren, and J. Sjöström et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review Br J Cancer 90 12 2004 2344 2348 [Review]
30. P. Regitnig, W. Schippinger, M. Lindbauer, H. Samonigg, and S.F. Lax Change of HER-2/neu status in a subset of distant metastases from breast carcinomas J Pathol 203 4 2004 918 926
31. B. Wang, Z.Z. Guan, and D.G. Liu et al. Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer Ai Zheng 23 12 2004 1710 1713
32. Y. Gong, D.J. Booser, and N. Sneige Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma Cancer 103 9 2005 1763 1769
33. E.E. Lower, E.L. Glass, D.A. Bradley, R. Blau, and S. Heffelfinger Impact of metastatic estrogen receptor and progesterone receptor status on survival Breast Cancer Res Treat 90 1 2005 65 70
34. J. Zidan, I. Dashkovsky, C. Stayerman, W. Basher, C. Cozacov, and A. Hadary Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease Br J Cancer 93 5 2005 552 556
35. D. Pectasides, A. Gaglia, and P. Arapantoni-Dadioti et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy Anticancer Res 26 1B 2006 647 653
36. C. Tapia, S. Savic, and U. Wagner et al. HER2 gene status in primary breast cancers and matched distant metastases Breast Cancer Res 9 3 2007 R31
37. C. Gomez-Fernandez, Y. Daneshbod, M. Nassiri, C. Milikowski, C. Alvarez, and M. Nadji Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer Am J Clin Pathol 130 6 2008 879 882
38. V. Guarneri, S. Giovannelli, and G. Ficarra et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management Oncologist 13 8 2008 838 844
39. A. Santinelli, E. Pisa, D. Stramazzotti, and G. Fabris HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy Int J Cancer 122 5 2008 999 1004
40. J.M. Wu, M.J. Fackler, and M.K. Halushka et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases Clin Cancer Res 14 7 2008 1938 1946
41. R.J. Broom, P.A. Tang, and C. Simmons et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer Anticancer Res 29 5 2009 1557 1562
42. C. Liedtke, K. Broglio, and S. Moulder et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann Oncol 20 12 2009 1953 1958
43. S.J. Aitken, J.S. Thomas, S.P. Langdon, D.J. Harrison, and D. Faratian Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases Ann Oncol 21 6 2010 1254 1261
44. E. Amir, W.S. Ooi, and C. Simmons et al. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies Clin Oncol (R Coll Radiol) 20 10 2008 763 768
45. J.F. Hilton, E. Amir, and S. Hopkins et al. Acquisition of metastatic tissue from patients with bone metastases from breast cancer Breast Cancer Res Treat 129 3 2011 761 765
46. P.K. Idirisinghe, A.A. Thike, and P.Y. Cheok et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance Am J Clin Pathol 133 3 2010 416 429
47. E. Sari, G. Guler, M. Hayran, I. Gullu, K. Altundag, and Y. Ozisik Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer Med Oncol 28 1 2011 57 63
48. A.M. Thompson, L.B. Jordan, and P. Quinlan et al. Breast Recurrence in Tissues Study Group. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) Breast Cancer Res 12 6 2010 R92
49. G. Bogina, L. Bortesi, and M. Marconi et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss Virchows Arch 459 1 2011 1 10
50. G. Curigliano, V. Bagnardi, and G. Viale et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 22 10 2011 2227 2233
51. Y. Gong, E.Y. Han, M. Guo, L. Pusztai, and N. Sneige Stability of estrogen receptor status in breast carcinoma: a comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy Cancer 117 4 2011 705 713
52. U. Wilking, E. Karlsson, and L. Skoog et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression Breast Cancer Res Treat 125 2 2011 553 561
53. E. Amir, N. Miller, and W. Geddie et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer J Clin Oncol 30 6 2012 587 592
54. V. Spataro, K. Price, and A. Goldhirsch et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group) Ann Oncol 3 9 1992 733 740
55. E. Montagna, V. Bagnardi, and N. Rotmensz et al. Breast cancer subtypes and outcome after local and regional relapse Ann Oncol 23 2 2012 324 331
56. L.S. Lindström, E. Karlsson, and U.M. Wilking et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression J Clin Oncol 30 21 2012 2601 2608
57. G. Viale, M.M. Regan, and E. Maiorano et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J Clin Oncol 25 25 2007 3846 3852
58. E.A. Perez, V.J. Suman, and N.E. Davidson et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial J Clin Oncol 24 19 2006 3032 3038
59. L. Pusztai, G. Viale, C.M. Kelly, and C.A. Hudis Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis Oncologist 15 11 2010 1164 1168
60. G.E. Gross, G.M. Clark, G.C. Chamness, and W.L. McGuire Multiple progesterone receptor assays in human breast cancer Cancer Res 44 2 1984 836 840
61. R.L. Balleine, M.J. Earl, M.L. Greenberg, and C.L. Clarke Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women Br J Cancer 79 9-10 1999 1564 1571
62. G. Aurilio, L. Monfardini, and S. Rizzo et al. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer Acta Oncol 52 8 2013 1649 1656
63. M.V. Dieci, E. Barbieri, and F. Piacentini et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis Ann Oncol 24 1 2013 101 108
64. N. Niikura, J. Liu, and N. Hayashi et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors J Clin Oncol 30 6 2012 593 599
65. C. Simmons, N. Miller, and W. Geddie et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 20 9 2009 1499 1504
66. S. Dawood, K. Broglio, A.U. Buzdar, G.N. Hortobagyi, and S.H. Giordano Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 1 2010 92 98